Peter Living Ordentlich from 28 Slocum Rd, Lexington, MA 02421, age 56, Phone: 7818627314

Resumes

Chief Scientific Officer

view source

Location:

28 Slocum Rd, Lexington, MA 02421

Industry:

Biotechnology

Work:

Syndax Pharmaceuticals since Oct 2005
Vice President, Translational Medicine
Salk Institute Feb 2005 - Oct 2005
Scientist
X-Ceptor Therapeutics Jan 2000 - Oct 2004
Research Scientist II
Salk Institute Sep 1997 - Dec 1999
Postdoctoral Fellow

Education:

University of Pennsylvania 1991 - 1997
Ph.D., Immunology University of Pennsylvania 1986 - 1990

Us Patents

Smrt Co-Repressors, Transcriptional Co-Repressors That Interact With Nuclear Hormone Receptors
view source
US Patent:

7314747, Jan 1, 2008
Filed:

Mar 10, 2000
Appl. No.:

09/522753
Inventors:

Ronald M. Evans - La Jolla CA, US
J. Don Chen - New Brunswick NJ, US
Peter Ordentlich - Solana Beach CA, US
Michael R. Downes - San Diego CA, US
Assignee:

The Salk Institute for Biological Studies - La Jolla CA
International Classification:

C12N 1/15
C12N 5/10
C12N 15/00
C07H 21/04
US Classification:

43525411, 435325, 4353201, 536 234, 536 235, 536 231
Abstract:

The present invention relates to isolated polynucleotides encoding a family of silencing mediators of retinoic acid and thyroid hormone receptor (SMRT) isoforms, including vertebrate and invertebrate isoforms thereof. The invention also relates to polypeptide SMRT co-repressors encoded by invention SMRT polynucleotides, and to peptide portions thereof that can modulate transcriptional potential of a nuclear receptor. In addition, the invention relates to chimeric molecules and to complexes containing a SMRT co-repressor or peptide portion thereof, to antibodies that specifically bind such compositions, and to methods for identifying an agent that modulates the repressor potential of a SMRT co-repressor. The invention also provides methods for identifying an agent that modulates a function of a SMRT co-repressor; for modulating the transcriptional potential of a nuclear receptor in a cell using the compositions of the invention; and for identifying a molecule that interacts specifically with a SMRT co-repressor.

Substituted Pyrimidine Compositions And Methods Of Use
view source
US Patent:

8455489, Jun 4, 2013
Filed:

Nov 9, 2004
Appl. No.:

10/595734
Inventors:

Richard Martin - San Diego CA, US
Raju Mohan - Encinitas CA, US
Peter Ordentlich - San Diego CA, US
Assignee:

Exelixis, Inc. - South San Francisco CA
International Classification:

C07D 239/34
A61K 31/505
A61P 25/00
A61P 25/16
A61P 25/18
A61P 29/00
A61P 35/00
US Classification:

514247, 544319, 514269
Abstract:

Novel compositions and methods of using substituted pyrimidines which have the general formula: (I).

Combination Of Era+ Ligands And Histone Deacetylase Inhibitors For The Treatment Of Cancer
view source
US Patent:

20080242648, Oct 2, 2008
Filed:

Nov 9, 2007
Appl. No.:

11/938130
Inventors:

Peter Ordentlich - San Diego CA, US
Joanna Horobin - Wellesley MA, US
Martha Jo Whitehouse - San Francisco CA, US
Miranda Rees - Mill Valley CA, US
Assignee:

Syndax Pharmaceuticals, Inc., a California Corporation - San Diego CA
International Classification:

A61K 31/565
A61K 31/4406
A61K 31/164
A61P 35/00
A61K 31/506
US Classification:

514171, 514357, 514275, 514616
Abstract:

The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.

Administration Of An Inhibitor Of Hdac And An Mtor Inhibitor
view source
US Patent:

20090149511, Jun 11, 2009
Filed:

Oct 29, 2008
Appl. No.:

12/260883
Inventors:

Konrad Burk - Madison CT, US
Peter Ordentlich - San Diego CA, US
Robert Goodenow - San Clemente CA, US
Assignee:

SYNDAX PHARMACEUTICALS, INC. - San Diego CA
International Classification:

A61K 31/44
A61P 35/04
US Classification:

514357
Abstract:

Methods of treating patients with an HDAC inhibitor and an mTOR inhibitor are provided.

Novel Compounds And Methods Of Using Them
view source
US Patent:

20100267779, Oct 21, 2010
Filed:

Jul 23, 2008
Appl. No.:

12/670390
Inventors:

John F.W. Keana - Eugene OR, US
Peter Ordentlich - San Diego CA, US
Robert Goodenow - San Clemente CA, US
Assignee:

SYNDAX PHARMACEUTICALS, INC. - San Diego CA
International Classification:

A61K 31/4406
C07D 213/56
A61P 35/00
US Classification:

514357, 546335
Abstract:

Described herein are novel HDAC inhibitors, formulations containing them and methods of using them. In some embodiments, the HDAC inhibitors possess specific stereochemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.

Novel Compounds And Methods Of Using Them
view source
US Patent:

20100298270, Nov 25, 2010
Filed:

Jul 23, 2008
Appl. No.:

12/670385
Inventors:

John F.W. Keana - Eugene OR, US
Peter Ordentlich - San Diego CA, US
Robert Goodenow - San Clemente CA, US
Assignee:

SYNDAX PHARMACEUTICALS, INC. - San Diego CA
International Classification:

A61K 31/675
C07D 401/12
A61K 31/444
A61P 35/00
C07D 213/89
A61K 31/4412
C07D 405/12
A61K 31/4433
C07D 309/40
A61K 31/351
C07F 9/30
A61K 31/662
C07D 413/12
A61K 31/5377
US Classification:

514 89, 546261, 514335, 546291, 514346, 5462821, 514336, 549418, 514460, 546 22, 560 29, 514119, 544131, 5142355
Abstract:

Described herein are novel HDAC modulators, formulations containing them and methods of using them. In some embodiments, the HDAC modulators possess specific stereo chemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.

Administration Of An Inhibitor Of Hdac
view source
US Patent:

20100305167, Dec 2, 2010
Filed:

Nov 19, 2008
Appl. No.:

12/743557
Inventors:

Konrad Burk - Madison CT, US
Peter Ordentlich - San Diego CA, US
Robert Goodenow - San Clemente CA, US
Assignee:

SYNDAX PHARMACEUTICALS, INC. - San Diego CA
International Classification:

A61K 31/4406
A61P 35/00
US Classification:

514357
Abstract:

Methods of treating patients with SNDX-275 are provided.

Administration Of An Inhibitor Of Hdac, An Inhibitor Of Her-2, And A Selective Estrogen Receptor Modulator
view source
US Patent:

20110182888, Jul 28, 2011
Filed:

Apr 7, 2009
Appl. No.:

12/936887
Inventors:

Peter Ordentlich - San Diego CA, US
Bob Goodenow - San Clemente CA, US
Bolin Liu - Centennial CO, US
Xiaoping Huang - Aurora CO, US
International Classification:

A61K 39/395
A61K 31/44
A61K 31/517
A61K 31/4709
A61K 31/4535
A61K 31/55
A61P 35/00
US Classification:

4241331, 514357, 51426624, 514313, 514326, 51421708
Abstract:

Methods of treating patients with an HDAC inhibitor and a HER-2 inhibitor are provided herein. In some embodiments, a SERM is also administered.

Peter Living Ordentlich

Peter Ordentlich Phones & Addresses

Work

Education

Industries

Resumes

Chief Scientific Officer

Us Patents

Smrt Co-Repressors, Transcriptional Co-Repressors That Interact With Nuclear Hormone Receptors

Substituted Pyrimidine Compositions And Methods Of Use

Combination Of Era+ Ligands And Histone Deacetylase Inhibitors For The Treatment Of Cancer

Administration Of An Inhibitor Of Hdac And An Mtor Inhibitor

Novel Compounds And Methods Of Using Them

Novel Compounds And Methods Of Using Them

Administration Of An Inhibitor Of Hdac

Administration Of An Inhibitor Of Hdac, An Inhibitor Of Her-2, And A Selective Estrogen Receptor Modulator